Skip to main content
Premium Trial:

Request an Annual Quote

LION Licenses New EST Clustering Software to Intervet: Mar 6, 2001 (rev. 1)

NEW YORK, March 6 – Lion Bioscience has licensed its soon-to-be launched EST clustering analysis software everEST, as well as genomeScout, its genome analysis software, to the Netherlands-based animal health company Intervet International, Lion said Tuesday.

The company has also extended licenses to Intervet for its SRS data integration platform and its bioScout genomic annotation system.

“Intervet is a valuable customer with a broad experience in bioinformatics,” Christian Marcazzo, Lion’s director of product marketing, told GenomeWeb.

Lion said this new extended software licensing agreement will provide additional revenue, but Marcazzo declined to comment on its financial terms.

Intervet is the second company to license and implement everEST. Lion has also installed the software, which it will officially launch this spring, at Nestle.

EverEST is designed to retrieve data from Lion’s SRS platform and perform EST clustering on it. “For the first time, the user can retrieve biological information concerning ESTs and EST consensus sequences from all major biological databases,” Marcazzo said. “Built-in applications can be launched to further analyze consensus sequences, such as BLAST or LION's annotation application bioScout.”

To perform the EST clustering in everEST Lion obtained a non-exclusive license to the StackPack clustering engine from Electric Genetics in South Africa last fall.

StackPack includes data management and visualization tools that enable researchers to rapidly cluster, align and analyze high volumes of ESTs and partial-length sequences. They highlight variations in transcripts and can accelerate gene discovery, gene function analysis, expression analysis and drug development.

Lion has established partnerships with a number of Life Science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithkline, Janssen, Merck, Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Sumitomo Pharmaceuticals, and Tripos. SRS is currently used by more than 30 life science organizations to integrate more than 400 different databases, the company said.
The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.